循環器ジャーナル71巻2号

2023年04月発行

特集 今だからこそ聞きたい心不全診療のこと。 Ⅲ．治療

うっ血を取りきることは本当に心不全の予後改善につながるか？

著者： 堀内優¹

所属機関： ¹三井記念病院循環器内科

ページ範囲：P.244 - P.250

POINT
・うっ血は心不全の病態の中心であり，利尿薬治療にもかかわらずうっ血が残存する患者は予後不良である．
・うっ血が取れるから予後が改善するのか，予後が良い患者のうっ血が改善しやすいのかはわからない．
・取れるうっ血は当然取るべきであるが，取れないうっ血にどう対応するかは今後の課題である．

参考文献

1）Zile MR, Bennett TD, St John Sutton M, et al. Transition from chronic compensated to acute decompensated heart failure : pathophysiological insights obtained from continuous monitoring of intracardiac pressures. Circulation 2008 ; 118 : 1433-41.

2）Horiuchi Y, Wettersten N, van Veldhuisen DJ, et al. Relation of Decongestion and Time to Diuretics to Biomarker Changes and Outcomes in Acute Heart Failure. Am J Cardiol 2021 ; 147 : 70-9.

3）Samsky MD, Dunning A, DeVore AD, et al. Liver function tests in patients with acute heart failure and associated outcomes : insights from ASCEND-HF. Eur J Heart Fail 2016 ; 18 : 424-32.

4）Wettersten N, Horiuchi Y, van Veldhuisen DJ, et al. Decongestion discriminates risk for one-year mortality in patients with improving renal function in acute heart failure. Eur J Heart Fail 2021 ; 23, 1122-30.

5）Rubio-Gracia J, Demissei BG, Ter Maaten JM, et al. Prevalence, predictors and clinical outcome of residual congestion in acute decompensated heart failure. Int J Card 2018 ; 258 : 185-91.

6）Januzzi JL Jr, Ahmad T, Mulder H, et al. Natriuretic Peptide Response and Outcomes in Chronic Heart Failure With Reduced Ejection Fraction. J Am Coll Cardiol 2019 ; 74 : 1205-17.

7）Felker GM, Anstrom KJ, Adams KF, et al. Effect of Natriuretic Peptide-Guided Therapy on Hospitalization or Cardiovascular Mortality in High-Risk Patients With Heart Failure and Reduced Ejection Fraction : A Randomized Clinical Trial. JAMA 2017 ; 318 : 713-20.

8）Stienen S, Salah K, Moons AH, et al. NT-proBNP（N-Terminal pro-B-Type Natriuretic Peptide）-Guided Therapy in Acute Decompensated Heart Failure : PRIMA II Randomized Controlled Trial（Can NT-ProBNP-Guided Therapy During Hospital Admission for Acute Decompensated Heart Failure Reduce Mortality and Readmissions?）. Circulation 2018 ; 137 : 1671-83.

9）Damman K, Testani JM. The kidney in heart failure : an update. Eur Heart J 2015 ; 36 : 1437-44.

10）Bart BA, Goldsmith SR, Lee KL, et al. Ultrafiltration in decompensated heart failure with cardiorenal syndrome. N Engl J Med 2012 ; 367 : 2296-304.

11）Wettersten N, Horiuchi Y, van Veldhuisen DJ, et al. B-type natriuretic peptide trend predicts clinical significance of worsening renal function in acute heart failure. Eur J Heart Fail 2019 ; 21 : 1553-60.

12)McCallum W, Tighiouart H, Testani JM, et al. Acute Kidney Function Declines in the Context of Decongestion in Acute Decompensated Heart Failure. JACC Heart Fail 2020 ; 8 : 537-47.

13）Rao VS, Ahmad T, Brisco-Bacik MA, et al. Renal Effects of Intensive Volume Removal in Heart Failure Patients With Preexisting Worsening Renal Function. Circ Heart Fail 2019 ; 12 : e005552.

14）Logeart D, Berthelot E, Bihry N, et al. Early and short-term intensive management after discharge for patients hospitalized with acute heart failure : a randomized study（ECAD-HF）. Eur J Heart Fail 2022 ; 24 : 219-26.

15）Abraham WT, Adamson PB, Bourge RC, er al. Wireless pulmonary artery haemodynamic monitoring in chronic heart failure : a randomised controlled trial. Lancet 2011 ; 377 : 658-66.

16）Costanzo MR, Stevenson LW, Adamson PB, et al. Interventions Linked to Decreased Heart Failure Hospitalizations During Ambulatory Pulmonary Artery Pressure Monitoring. JACC Heart Fail 2016 ; 4 : 333-44.

17）Mullens W, Damman K, Harjola VP, et al. The use of diuretics in heart failure with congestion-a position statement from the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail 2019 ; 21 : 137-55.

18）Ellison DH, Felker GM. Diuretic Treatment in Heart Failure. N Engl J Med 2017 ; 377 : 1964-75.

19）Jentzer JC, DeWald TA, Hernandez AF. Combination of loop diuretics with thiazide-type diuretics in heart failure. J Am Coll Cardiol 2010 ; 56 : 1527-34.

20）Konstam MA, Gheorghiade M, Burnett JC Jr, et al. Effects of oral tolvaptan in patients hospitalized for worsening heart failure : the EVEREST Outcome Trial. JAMA 2007 ; 297 : 1319-31.

21）Butler J, Anstrom KJ, Felker GM, et al. Efficacy and Safety of Spironolactone in Acute Heart Failure : The ATHENA-HF Randomized Clinical Trial. JAMA Cardiol 2017 ; 2 : 950-8.

22）Mullens W, Dauw J, Martens P, et al. Acetazolamide in Acute Decompensated Heart Failure with Volume Overload. N Engl J Med 2022 ; 387 : 1185-95.

23）Voors AA, Angermann CE, Teerlink JR, et al. The SGLT2 inhibitor empagliflozin in patients hospitalized for acute heart failure : a multinational randomized trial. Nat Med 2022 ; 28 : 568-74.

24）Solomon SD, McMurray JJV, Anand IS, et al. Angiotensin-Neprilysin Inhibition in Heart Failure with Preserved Ejection Fraction. N Engl J Med 2019 ; 381 : 1609-20.